Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

st

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on February 24, 2009 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until March 10, 2009.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, w
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 International research ... announced that its biobanking project, Provia Laboratories , ... its growing Advisory Board. Scott Wolf , CEO ... have Dr. Vaught onboard with Provia’s ever-expanding Advisory Board. ... that Provia’s management team brings to this field, should ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are ... for the long term. They are the first functional ... sustained energy as an alternative to the temporary fix ... on Indiegogo on July 29, 2014, with hopes to ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... de julio de 2014 ADB International ... ha anunciado hoy una asociación con Austen BioInnovation ... o el Instituto), para el propósito de llevar ... terapia de señal bioeléctrica (el E-QURE BST Device), ... que tiene una importante experiencia en cicatrización de ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
Breaking Biology Technology:Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Entomologists at the University of California, Riverside working on ... of compounds that could pave the way for developing inexpensive ... other deadly tropical diseases. When fruit flies undergo stress, ... a warning to other fruit flies that danger or predators ...
... HARBIN, China, Aug. 26 ... One Medical" or "the Company") (Nasdaq: ... over-the-counter,drugs in the People,s Republic of China ("PRC"), ... been raised with respect to financial reports filed,with ...
... , PARIS, August 26 , - Net Profit Up 11%, - Strong Research ... The Board of Directors, meeting on 25 August 2009 under the chairmanship,of Albert Saporta approved the 2009 half year financial ... 08/07 H1 2009, ... Var.% %CA, Sales ...
Cached Biology Technology:Discovery of natural odors could help develop mosquito repellents 2Discovery of natural odors could help develop mosquito repellents 3China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 2China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 4
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today announced ... University of Massachusetts Amherst School of Public Health ... $700,000 Science to Achieve Results (STAR) grant to ... Native subsistence hunters in subarctic North America to ... and to provide culturally-relevant recommendations for mitigation. , ...
(Date:7/23/2014)... Mass. Honey bees, especially the young, are highly ... work together to maintain temperatures within a narrow range. ... biologist at Tufts University,s School of Arts and Sciences, ... excess heat within a hive in process similar to ... blood vessels and skin. , "This study shows ...
(Date:7/23/2014)... cultured from cystic fibrosis patients, scientists at the UNC ... have shown that a new CF drug counteracts the ... The finding, published today in the journal Science ... becomes unstable and loses its ability to function properly ... research offers several insights into how novel CF pharmacotherapies ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3How honey bees stay cool 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... in extreme cold, scientists no longer have to go ... Bacteria previously isolated from polar climates, and have properties ... been isolated from soil in temperate environments. , Professor ... have developed a technique to isolate bacteria which have ...
... the four bacterial surface proteins that generate the ... University of Chicago have created a vaccine that ... strains of Staphylococcus aureus, the most common cause ... of community-associated illness. , The vaccine protected ...
... The repeated copying of a small segment of DNA in ... to the transition of ancient animals from sea to land, ... discovery is "tantalizing evidence" that copied DNA elements known as ... the director of the research, Howard Hughes Medical Institute investigator ...
Cached Biology News:MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4
... Works fast and effectively in tubes and ... and simple, one tube, one and a half ... to clean up or concentrate any type of ... primers, primer dimers or dNTPs (labelled or unlabelled). ...
... holds 96 x 0.2 ml tubes or ... incorporates a thumbwheel to adjust height and ... oil-free cycling. Peltier heat pumps produce uniform, ... rates of up to 1.4 degrees C ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
Sf21 Insect Cells (Live) in Max-XP Medium...
Biology Products: